Just is seeking a highly motivated Principal Scientist who desires a significant opportunity to improve worldwide access to biotherapeutics. The candidate will join a fast-paced, collaborative, and multi-disciplinary team focused on developing and advancing biotherapeutics from discovery to First-in-Human. The successful candidate will lead the execution of preclinical cell-based activity studies, antigen binding studies and in vivo efficacy studies. A strong foundation in target biology, cell-based assay development, in vitro functional assays and immunoassays is required for this position, as well as strong experimental design and data analysis skills. Previous industry experience in therapeutic antibody preclinical development and prior experience working with CROs is highly desirable.
Responsibilities:
- Lead the design and implementation of antigen binding studies, in vitro cell-based functional assays and in vivo efficacy studies to screen and characterize antibody therapeutics
- Design and conduct mechanistic studies to elucidate the mechanism of action of biotherapeutics, based on target biology and target product profile
- Read scientific literature, keep abreast of science and technology developments in the field and implement appropriately for optimal program development
- Interface and conduct preclinical studies with external partners, as well as CROs
- Analyze, organize, summarize, and present data and results at department and project team meetings
- Maintain a detailed and organized record of experiments in an electronic notebook
Qualifications and Education Requirements:
- Ph.D. degree in life sciences, cellular biology, immunology, pharmacology or other related discipline with minimum of 5 years of relevant experience
- Experience identifying, designing and implementing mechanistic assays based on target biology
- Experience with animal models of disease and designing in vitro and in vivo studies to address efficacy of therapeutics
- Experience with developing and implementing cell-based functional assays, immunoassays (ELISA, AlphaLISA) and protein binding kinetic assays (BLI, SPR)
- Knowledge of Fc effector function pathways and associated assays (ADCC, CDC, ADCP)
- Excellent verbal and written communication skills
- Strong focus on quality and attention to detail
- Possess effective task/time management organizational skills
- Ability to work in teams as well as independently
Preferred Qualifications:
- Experience with preclinical development of antibody therapeutics
- Experience conducting in vitro and/or in vivo pharmacology studies in conjunction with external partners or CROs
- Experience with the assembly of data and associated reports to support FDA filings regulatory
- Experience with GLP regulations
The base pay range for this position at commencement of employment is expected to be $140,000 to $170,000; Base salary offered may vary depending on individual’s skills, experience and competitive market value. Additional total rewards include discretionary annual bonus, comprehensive benefits to include Medical, Dental and Vision, short-term and long-term disability, company paid basic life insurance, 401k company match, flexible work, generous paid time off and paid holiday, wellness and transportation benefits.
Note: We will be arranging screening in December for suitable candidates, 1st Interview stage will take place in January 2025. Like is due to the Christmas holidays.
Evotec (US) Inc. is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, gender, age, disability, genetic information, gender expression, gender identity, national origin, religion, sexual orientation, or veteran status.
Top Skills
What We Do
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients.
Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing.
We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI.
We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
